Literature DB >> 33625578

Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Thomas Wiegel1, Peter Albers2, Detlef Bartkowiak3, Roswitha Bussar-Maatz4, Martin Härter5, Glen Kristiansen6, Peter Martus7, Stefan Wellek8, Heinz Schmidberger9, Klaus Grozinger10, Peter Renner11, Fried Schneider12, Martin Burmester13, Michael Stöckle14.   

Abstract

Entities:  

Year:  2021        PMID： 33625578      PMCID： PMC7954727          DOI： 10.1007/s00432-021-03549-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  4 in total

1.  Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

Authors:  David E Neal; Chris Metcalfe; Jenny L Donovan; J Athene Lane; Michael Davis; Grace J Young; Susan J Dutton; Eleanor I Walsh; Richard M Martin; Tim J Peters; Emma L Turner; Malcolm Mason; Richard Bryant; Prasad Bollina; James Catto; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Peter Holding; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Jon Oxley; Alan Paul; Edgar Paez; Derek J Rosario; Edward Rowe; John Staffurth; Doug G Altman; Freddie C Hamdy
Journal:  Eur Urol       Date:  2019-11-24       Impact factor: 20.096

2.  Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial).

Authors:  Andreas Boehle; Frank Kahmann; Thomas Oliver Henkel; Joerg Zimmermann; Stefan Machtens
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-28       Impact factor: 4.553

3.  Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Authors:  Thomas Wiegel; Peter Albers; Detlef Bartkowiak; Roswitha Bussar-Maatz; Martin Härter; Glen Kristiansen; Peter Martus; Stefan Wellek; Heinz Schmidberger; Klaus Grozinger; Peter Renner; Fried Schneider; Martin Burmester; Michael Stöckle
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-04       Impact factor: 4.553

4.  Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.

Authors:  Peter Albers; Thomas Wiegel; Heinz Schmidberger; Roswitha Bussar-Maatz; Martin Härter; Glen Kristiansen; Peter Martus; Christoph Meisner; Stefan Wellek; Klaus Grozinger; Peter Renner; Martin Burmester; Fried Schneider; Michael Stöckle
Journal:  World J Urol       Date:  2020-03-18       Impact factor: 4.226
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.